-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to Merck Sharp & Dohme China's WeChat public account news on the 11th, recently, Merck Sharp & Dohme China noticed that some manufacturers supply new crown drugs to some provinces and cities under the banner of "Merck Sharp & Dohme Authorization" and "Merck Donation", Merck Sharp & Dohme China solemnly declares:
1.
The generic name of Merck's oral new crown drug is monoravir capsules, the trade name is Lizhuorui ®, and there are no other Chinese names
.
The generic name of Merck's oral new crown drug is monoravir capsules, the trade name is Lizhuorui ®, and there are no other Chinese names
.
2.
Merck new crown drugs are packaged in strict accordance with the documents approved by the state, and all products are assigned drug traceability codes
.
Merck new crown drugs are packaged in strict accordance with the documents approved by the state, and all products are assigned drug traceability codes
.
3.
Sinopharm Distribution Center Co.
, Ltd.
is the only legally authorized importer of Merck in China and is responsible for distribution to downstream distributors
.
Merck has never authorized other domestic manufacturers to produce or imitate monolavir and supply
it to the Chinese market.
Sinopharm Distribution Center Co.
, Ltd.
is the only legally authorized importer of Merck in China and is responsible for distribution to downstream distributors
.
Merck has never authorized other domestic manufacturers to produce or imitate monolavir and supply
it to the Chinese market.
4.
In order to meet the needs of Chinese patients and help China fight the new crown epidemic, Merck has started production technology licensing negotiations with Sinopharm so that Sinopharm can produce and supply the drug
in China in the future.
In order to meet the needs of Chinese patients and help China fight the new crown epidemic, Merck has started production technology licensing negotiations with Sinopharm so that Sinopharm can produce and supply the drug
in China in the future.
In its statement, Merck China calls on and sincerely hopes that all pharmaceutical production/trading enterprises and drug procurement and sales platforms will respect the legitimate rights and interests of enterprises and jointly maintain the legal and fair business order
of the domestic pharmaceutical market.
Drugs through informal channels have not been approved by the national drug regulatory authorities, and their production, quality and efficacy cannot be guaranteed, which poses great hidden dangers
to patients' medication and medical safety.
For the infringement of some pharmaceutical companies, Merck will take necessary legal measures
.
of the domestic pharmaceutical market.
Drugs through informal channels have not been approved by the national drug regulatory authorities, and their production, quality and efficacy cannot be guaranteed, which poses great hidden dangers
to patients' medication and medical safety.
For the infringement of some pharmaceutical companies, Merck will take necessary legal measures
.
Merck China said that Molnupiravir capsules (trade name: Leadury ®/LAGEVRIO)® is an anti-new coronavirus oral drug jointly developed by Merck and Ridgeback Biotechnology, which was approved by China's National Medical Products Administration on December 29
, 2022.
At present, Merck is actively stocking to ensure the orderly supply
of drugs.
, 2022.
At present, Merck is actively stocking to ensure the orderly supply
of drugs.
